Dave MacMillan received his undergraduate degree in chemistry at the University of Glasgow, where he worked with Dr. Ernie Colvin. In 1990, he left the UK to begin his doctoral studies under the direction of Professor Larry Overman at the University of California, Irvine. In 1996, he moved to a postdoctoral position with Professor Dave Evans at Harvard University where his studies centered on enantioselective catalysis. He began his independent career at University of California, Berkeley in July of 1998 before moving to the California Institute of Technology in June of 2000. In 2003, he was promoted to Full Professor at Caltech, before being appointed the Earle C. Anthony Chair of Organic Chemistry in 2004. In 2006, Dave moved to the east coast of the US to take up a position at Princeton University as the A. Barton Hepburn Chair of Chemistry and Director of the Merck Center for Catalysis at Princeton University. He also became the Princeton Chemistry Department Chair in July of 2010. The MacMillan research program is centered on chemical synthesis with specific interests in new reaction development, enantioselective organocatalysis and the rapid construction of molecular complexity.

Dave has received several awards including the ACS Award for Creative Work in Organic Synthesis (2011), Mukaiyama Award (2007), ISHC Award in Heterocyclic Chemistry (2007), ACS Cope Scholar Award (2007), Thieme-IUPAC Prize in Organic Synthesis (2006), Elias J. Corey Award for Outstanding Original Contribution in Organic Synthesis by a Young Investigator (2005), the Tetrahderon Young Investigator Award (2005), the Corday-Morgan Medal (2005), Henry Dreyfus Teacher-Scholar Award (2003), a Sloan Fellowship (2002), and a Woodward Scholarship Award from Harvard University (2001). Dave is currently editor-in-chief of the new RSC journal "Chemical Sciences" and is a member of the Chemical Communications, Tetrahedron, Tetrahedron Letters, Chemistry-an Asian Journal, Advances in Catalysis and Synthesis editorial advisory boards. Dave is a co-founder of Chiromics LLC and is a member of the scientific advisory board of Lexicon pharmaceuticals and a permanent member of the RSRC board (Chemistry SAB) at Merck. Dave is currently a scientific consultant with Merck (worldwide), Amgen (worldwide), Abbott Research Laboratories, Johnson & Johnson Pharmaceuticals, Constellation Pharmaceuticals and Gilead Research Laboratories.

Paul J. Reider joined the faculty of Princeton University in 2008 where his research is focused on new drugs for Malaria, TB and other neglected diseases. During his 28 years in the pharmaceutical industry he has directly contributed to the discovery, identification, development or registration of 14 approved drugs [SINGULAIR, CRIXIVAN, PRIMAXIN, SUSTIVA/STOCRIN, INVANZ, COZAAR, AGGRASTAT, CANCIDAS, VIOXX, ARCOXIA, MAXALT, JANUVIA, EMEND and SENSIPAR]. From 2002-2007 he was at Amgen as Worldwide Head of Chemistry Research & Discovery. At Amgen he built and led a team of nearly 600 located in Thousand Oaks, San Francisco, Seattle, Cambridge (MA) and Regensburg, Germany.

He received his A.B. (Psychology) at New York University's Washington Square College and his Ph.D. (Organic Chemistry) at the University of Vermont. After post-doctoral research as an NIH National Research Service Awardee at Colorado State University, Paul joined Merck as a Senior Research Chemist in Process Chemistry where he remained for 22 years. Prior to joining Amgen, he was Vice President of Process Chemistry at Merck. Paul is an inventor on many patents, an author of more than 170 scientific papers, and the winner of numerous awards. Most recently, he was named the winner of the 2011 National Academy of Sciences' Award for Chemistry in Service to Society. He's served on the visiting committees for Harvard University, California Institute of Technology, and the University of California, Santa Barbara, and on the Editorial Advisory Boards of the Journal of the American Chemical Society, the Journal of Organic Chemistry, and Organic Letters. He is also a Senior Editor of Current Opinion in Drug Discovery & Development, and Science of Synthesis. In 2011, Paul joined the Scientific Advisory Boards of the Medicines for Malaria Venture and the TB Alliance.

Hahn Kim is a co-founder of Chiromics. He was crucial in the development of the proprietary science and technology of Chiromics and currently oversees all of Chiromics' operations and business strategies.

He received his B.S.& M.S (Chemistry) from Seoul National University and received his doctorate in synthetic organic chemistry from Princeton University. Prior to his current role, he was a NIH/NCI postdoctoral fellow in the MacMillan labs. Dr. Kim is also a co-founder of Crescenta Biosciences, the Founding Director of the Princeton University Small Molecule Screening Center and an associate member of the Rutgers Cancer Institute of New Jersey.